GHENT, Belgium, 7 September 2017 – Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announces that it will participate in the following upcoming investor conferences taking place in London, UK:
- J.P. Morgan’s London Small/Mid Cap Conference: one-on-one meetings with institutional investors are scheduled for Thursday 14 September 2017.
- Bank of America Merrill Lynch (BAML) Global Healthcare Conference: a presentation is scheduled for Friday 15 September 2017 at 01.45 p.m. GMT (02.45 p.m. Central European Time), followed by a breakout session, together with one-on-one meetings with institutional investors. The slides will be available, shortly after the presentation is given, on the Company’s website, under the News & Events section.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/92d514e5-7f55-4401-8d6b-8febc16c5d76
